UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
   Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934


         Date of Report (Date of earliest event reported): March 1, 2006


                                 OPTIGENEX INC.
               (Exact name of registrant as specified in charter)


           Delaware                  000-51248                20-1678933
(State or other jurisdiction       (Commission              (IRS Employer
       of incorporation)           File Number)           Identification No.)


           750 Lexington Avenue 6th Floor, New York               10022
           (Address of principal executive offices)             (Zip Code)


       Registrant's telephone number, including area code: (212) 905-0189

                                   Copies to:
                             Gregory Sichenzia, Esq.
                               Louis A. Brilleman
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 1.01 Entry into a Material Definitive Agreement.

      On March 1, 2006, the Board of Directors (the "Board") of Optigenex Inc.
(the "Company") took the following actions with respect to incentive
compensation and salaries for the following executive officers :

      o     CEO Employment Agreement: The Board approved an extension of the
            employment agreement with Anthony Bonelli, its CEO and President,
            until February 16, 2008. His employment agreement calls for a base
            salary of $300,000 and an annaul bonus of $100,000 payable in
            quarterly installments. His original employment expired on August
            16, 2005 and was initially extended until February 16, 2006. All
            other terms and conditions contained in the employment agreement
            remain in effect;

      o     Stock Options: The Board approved issues of options to the following
            Executive Officers

<TABLE>
<CAPTION>
                                    Quantity               Exercise Price               Vesting
                                    --------               --------------               -------
<S>                                 <C>                       <C>                       <C>
         Anthony Bonelli            500,000                   $  .13                    Immediately
                                    250,000                    $1.00                    February 28,2007
                                    250,000                    $1.00                    February 28,2008


         Joseph McSherry            300,000                   $  .13                    Immediately
                                    100,000                    $1.00                    February 28, 2007
                                    100,000                    $1.00                    February 28, 2008
</TABLE>


Item 9.01 Financial Statements and Exhibits.

      (a)   Financial statements of business acquired.

            None

      (b)   Pro forma financial information.

            None

      (c)   Exhibits.

            None.

<PAGE>

                                   SIGNATURES


      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                                Optigenex, Inc.


Date: March 6, 2006                            By: /s/ Joe McSherry
                                                   -----------------------
                                                   Chief Financial Officer
{"company-data": {"conformed-name": "OPTIGENEX INC.", "cik": "0001168776", "assigned-sic": "2833", "irs-number": "201678933", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51248", "film-number": "06670778"}, "business-address": {"street1": "750 LEXINGTON AVENUE", "street2": "6TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022", "phone": "212-905-0189"}, "mail-address": {"street1": "750 LEXINGTON AVENUE", "street2": "6TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022"}, "former-company": {"former-conformed-name": "VIBRANT HEALTH INTERNATIONAL", "date-changed": "20020308"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
   Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

         Date of Report (Date of earliest event reported): March 1, 2006

                                 OPTIGENEX INC.
               (Exact name of registrant as specified in charter)

           Delaware                  000-51248                20-1678933
(State or other jurisdiction       (Commission              (IRS Employer
       of incorporation)           File Number)           Identification No.)

           750 Lexington Avenue 6th Floor, New York               10022
           (Address of principal executive offices)             (Zip Code)

       Registrant's telephone number, including area code: (212) 905-0189

                                   Copies to:
                             Gregory Sichenzia, Esq.
                               Louis A. Brilleman
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.

      On March 1, 2006, the Board of Directors (the "Board") of Optigenex Inc.
(the "Company") took the following actions with respect to incentive
compensation and salaries for the following executive officers :

      o     CEO Employment Agreement: The Board approved an extension of the
            employment agreement with Anthony Bonelli, its CEO and President,
            until February 16, 2008. His employment agreement calls for a base
            salary of $300,000 and an annaul bonus of $100,000 payable in
            quarterly installments. His original employment expired on August
            16, 2005 and was initially extended until February 16, 2006. All
            other terms and conditions contained in the employment agreement
            remain in effect;

      o     Stock Options: The Board approved issues of options to the following
            Executive Officers
Quantity               Exercise Price               Vesting
                                    --------               --------------               -------
Anthony Bonelli            500,000                   $  .13                    Immediately
                                    250,000                    $1.00                    February 28,2007
                                    250,000                    $1.00                    February 28,2008

         Joseph McSherry            300,000                   $  .13                    Immediately
                                    100,000                    $1.00                    February 28, 2007
                                    100,000                    $1.00                    February 28, 2008
Item 9.01 Financial Statements and Exhibits.

      (a)   Financial statements of business acquired.

            None

      (b)   Pro forma financial information.

            None

      (c)   Exhibits.

            None.
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                Optigenex, Inc.

Date: March 6, 2006                            By: /s/ Joe McSherry
                                                   -----------------------
                                                   Chief Financial Officer